A.I.-guided Chemo Halts Disease Worsening in Patient with mPRPC, Study Reports

A.I.-guided Chemo Halts Disease Worsening in Patient with mPRPC, Study Reports
An artificial intelligence (A.I.) platform called CURATE.AI may be used to determine the optimal doses of investigational therapy ZEN-3694 and Xtandi (enzalutamide) to be given to patients with metastatic castration-resistant prostate cancer (mCRPC). The approach led to a complete and durable halt of disease progression in a patient included in a Phase 1/2 trial. The research, “Modulating BET Bromodomain Inhibitor ZEN-3694 and Enzalutamide Combination Dosing in
Subscribe or to access all post and page content.

2 comments

Leave a Comment

Your email address will not be published. Required fields are marked *